The California Public Employees’ Retirement System alleged in a lawsuit that Bristol-Myers Squibb Co.’s Celgene fraudulently misled investors about the potential of two new drugs to offset a sales slowdown from the company’s blockbuster multiple myeloma drug, Revlimid, which is slated to lose patent protection next year.

The Department of Health and Human Services overturned Friday a last-minute approval by the Trump administration extending Texas’s Medicaid plan for 10 years.

The FDA on Friday revoked its authorization for Eli Lilly’s Covid-19 antibody product bamlanivimab to be used on its own.

Attorneys should carefully evaluate which issues of a patent case are most likely to get traction on appeal, Federal Circuit Judge Kimberly A. Moore says.

In a Hail Mary attempt to control a third wave of Covid-19, Ontario unveiled its strictest measures yet to restrict the movement of people, setting up checkpoints with neighboring Quebec and Manitoba for the first time in the pandemic.

NIH-funded scientists who want to use fetal tissue in their studies will no longer face Trump-era restrictions favored by abortion opponents.